Clopidogrel does not benefit infants with congenital heart disease

06/19/2013 |

Clopidogrel therapy did not yield better outcomes for babies with cyanotic congenital heart disease and a systemic-to-pulmonary-artery shunt compared with placebo and conventional treatment, a study showed. Rates of death, overall bleeding and severe bleeding were similar for both clopidogel and placebo groups, researchers reported in the New England Journal of Medicine.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI